- Odyssey, on second try, snags $279M in an IPO<figure><div><img src="https://imgproxy.divecdn.com/szYDL8kkQd6XaSVgvjJPYl2j0snveijWs_0sZ-B522Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDYyODUzODA3LmpwZ…BioPharma Dive · 2mo ago↗ source
- <![CDATA[Dr Sznol on Optimal Treatment Sequencing in Melanoma]]><![CDATA[Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data. ]]>onclive · 2mo ago↗ source
- <![CDATA[Mentorship Is Key to Advance the Next Generation of Oncology Researchers]]><![CDATA[Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators. ]]>onclive